Biomaterial Database

[The protective effect of low molecular weight heparin on early nephropathy in diabetic rats]. 2001

H Guo, and L Gan, and Z Yu

Renal Division, People's Hospital, Peking University, Beijing, China.

OBJECTIVE To investigate the protective effect of low molecular heparin on early nephropathy in diabetic rats and to explore its possible mechanism. METHODS The rats were randomly divided into following groups: normal control rats, streptozotocin (STZ, 65 mg/kg)-induced diabetic rats and diabetic rats treated with low molecular weight heparin (Fraxiparine, Nadroparin calcium 205 AXaIU/kg). The activity of anti-Xa factor and the activated partial thromboplastin time (APIT) in plasma were assayed, the renal function and profile of kidney hypertrophy were measured, and the renal tissue were observed by light microscopy after 1, 2, 4 weeks of the treatment respectively. RESULTS Compared with the untreated diabetic group, except for higher kidney hypertrophy index, LMWH treated diabetic rats presented less urinary albumin excretion, lower creatinine clearance rate (Ccr) and longer APTT than diabetic group without any treatment. Meanwhile, renal pathologic changes in LMWH treated group were improved. CONCLUSIONS Low molecular weight heparin possesses a renal protective effect on early diabetic nephropathy and its possible mechanism may be associated with the beneficial effect of LMWH on regulating abnormal diabetic renal hemodynamics.

UI	MeSH Term	Description	Entries
D007668	Kidney	Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.	Kidneys
D008297	Male		Males
D003921	Diabetes Mellitus, Experimental	Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.	Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003928	Diabetic Nephropathies	KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D006495	Heparin, Low-Molecular-Weight	Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.	LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D017207	Rats, Sprague-Dawley	A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.	Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381	Rats	The common name for the genus Rattus.	Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

H Guo, and L Gan, and Z Yu

[The protective effect of low molecular weight heparin on nephropathy in rats with pregnancy induced hypertension].

May 2005, Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,

H Guo, and L Gan, and Z Yu

[Effects of low molecular weight heparin on vascular endothelial growth factor expression of early diabetic nephropathy].

August 2005, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences,

H Guo, and L Gan, and Z Yu

Protective effect of low-molecular-weight heparin on pancreatic encephalopathy in severe acute pancreatic rats.

November 2012, Inflammation research : official journal of the European Histamine Research Society ... [et al.],

H Guo, and L Gan, and Z Yu

Low molecular weight proteinuria in diabetic children--a marker of early diabetic nephropathy?

January 1985, Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress,

H Guo, and L Gan, and Z Yu

Protective effect of herbomineral formulation (Dolabi) on early diabetic nephropathy in streptozotocin-induced diabetic rats.

July 2012, Journal of natural medicines,

H Guo, and L Gan, and Z Yu

Protective effect of ultra low molecular weight heparin on glutamate-induced apoptosis in cortical cells.

June 2008, Yonsei medical journal,

H Guo, and L Gan, and Z Yu

Protective effect of yacon leaves decoction against early nephropathy in experimental diabetic rats.

May 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,

H Guo, and L Gan, and Z Yu

Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.

February 2008, Diabetes care,